Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Accumulated Expenses (2016 - 2025)

Angiodynamics (ANGO) has disclosed Accumulated Expenses for 15 consecutive years, with $29.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 25.22% year-over-year to $29.9 million, compared with a TTM value of $29.9 million through Nov 2025, down 25.22%, and an annual FY2025 reading of $35.5 million, down 13.58% over the prior year.
  • Accumulated Expenses was $29.9 million for Q4 2025 at Angiodynamics, up from $27.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $41.1 million in Q2 2024 and bottomed at $21.8 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $30.6 million, with a median of $29.5 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses skyrocketed 54.41% in 2024, then decreased 25.22% in 2025.
  • Year by year, Accumulated Expenses stood at $27.7 million in 2021, then dropped by 4.26% to $26.5 million in 2022, then grew by 10.19% to $29.2 million in 2023, then surged by 36.54% to $39.9 million in 2024, then fell by 25.22% to $29.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for ANGO at $29.9 million in Q4 2025, $27.7 million in Q3 2025, and $35.5 million in Q2 2025.